The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Immune suppression in gliomas
Open accessAbstract
Introduction: The overall survival in patients with gliomas has not significantly increased in the modern era, despite advances such as immunotherapy. This is in part due to their notorious ability to suppress local and systemic immune responses, severely restricting treatment efficacy. Methods: We have reviewed the preclinical and clinical evidence for immunosuppression seen throughout the disease process in gliomas. This review aims to discuss the various ways that brain tumors, and gliomas in particular, co-opt the body’s immune system to evade detection and ensure tumor survival and proliferation. Results: A multitude of mechanisms are discussed by which neoplastic cells evade detection and destruction by the immune system. These include tumor-induced T-cell and NK cell dysfunction, regulatory T-cell and myeloid-derived suppressor cell expansion, M2 phenotypic transformation in glioma-associated macrophages/microglia, upregulation of immunosuppressive glioma cell surface factors and cytokines, tumor microenvironment hypoxia, and iatrogenic sequelae of immunosuppressive treatments. Conclusions: Gliomas create a profoundly immunosuppressive environment, both locally within the tumor and systemically. Future research should aim to address these immunosuppressive mechanisms in the effort to generate treatment options with meaningful survival benefits for this patient population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., Stanley, E. R., et al. (2010) · Science · doi:10.1126/science.1194637 · Cited by 5,175
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
Vignali, D. A. A., Collison, L. W., & Workman, C. J. (2008) · Nature Reviews Immunology · doi:10.1038/nri2343 · Cited by 3,463
Hypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
The role of microglia and macrophages in glioma maintenance and progression
Hambardzumyan, D., Gutmann, D. H., & Kettenmann, H. (2016) · Nature Neuroscience · doi:10.1038/nn.4185 · Cited by 1,683
Wherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R., & Ahmed, R. (2003) · Journal of Virology · doi:10.1128/jvi.77.8.4911-4927.2003 · Cited by 1,610
Schwartz, R. H. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141110 · Cited by 1,487
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation
Solinas, G., Germano, G., Mantovani, A., & Allavena, P. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0609385 · Cited by 1,425
The impact of O2 availability on human cancer
Bertout, J. A., Patel, S. A., & Simon, M. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2540 · Cited by 1,365
Talks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., & Harris, A. L. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64554-3 · Cited by 1,312
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
Age-related changes in lymphocyte development and function
Linton, P. J., & Dorshkind, K. (2004) · Nature Immunology · doi:10.1038/ni1033 · Cited by 1,181
Yang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., & Lin, P. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.031 · Cited by 1,140
Regulatory T cells exert checks and balances on self tolerance and autoimmunity
Wing, K., & Sakaguchi, S. (2010) · Nature Immunology · doi:10.1038/ni.1818 · Cited by 1,107
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Marvel, D., & Gabrilovich, D. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80005 · Cited by 1,050
L-arginine availability regulates T-lymphocyte cell-cycle progression.
Rodriguez, P. C., Quiceno, D. G., & Ochoa, A. C. (2007) · Blood · doi:10.1182/blood-2006-06-031856 · Cited by 926
Murdoch, C., Giannoudis, A., & Lewis, C. E. (2004) · Blood · doi:10.1182/blood-2004-03-1109 · Cited by 915
Strand, S., Hofmann, W. J., Hug, H., Müller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H., & Galle, P. R. (1996) · Nature Medicine · doi:10.1038/nm1296-1361 · Cited by 897
Increase of regulatory T cells in the peripheral blood of cancer patients.
Wolf, A. M., Wolf, D. G. F., Steurer, M., Gastl, G. A., Gunsilius, E., & Grubeck-Loebenstein, B. (2003) · PubMed · Cited by 891
The Transcription Factor NFAT Promotes Exhaustion of Activated CD8 + T Cells
Martinez, G. J., Pereira, R. M., Äijö, T., Kim, E. Y., Marangoni, F., Pipkin, M. E., Togher, S., Heissmeyer, V., Zhang, Y. C., Crotty, S., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.006 · Cited by 857 · cited 1×
“While in the exhausted state, failure of NFAT to form a complex with AP-1 results in expression of inhibitory immune checkpoints, such as PD-1 and CTLA-4 [18].”
BackgroundEpidemiology of primary brain tumors: Current concepts and review of the literature
Wrensch, M., Minn, Y., Chew, T., Bondy, M., & Berger, M. S. (2002) · Neuro-Oncology · doi:10.1093/neuonc/4.4.278 · Cited by 837
MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells
Karlhofer, F. M., Ribaudo, R. K., & Yokoyama, W. M. (1992) · Nature · doi:10.1038/358066a0 · Cited by 797
SERAFINI, P., BORRELLO, I., & BRONTE, V (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.005 · Cited by 762
Tolerance and exhaustion: defining mechanisms of T cell dysfunction
Schietinger, A., & Greenberg, P. D. (2014) · Trends in Immunology · doi:10.1016/j.it.2013.10.001 · Cited by 673
Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors
Chongsathidkiet, P., Jackson, C., Koyama, S., Loebel, F., Cui, X., Farber, S. H., Woroniecka, K., Elsamadicy, A. A., Dechant, C. A., Kemeny, H. R., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0135-2 · Cited by 668
Self-citationT-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
Woroniecka, K., Chongsathidkiet, P., Rhodin, K., Kemeny, H., Dechant, C., Farber, S. H., Elsamadicy, A. A., Cui, X., Koyama, S., Jackson, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1846 · Cited by 654
Self-citationFecci, P. E., Mitchell, D. A., Whitesides, J. F., Xie, W., Friedman, A. H., Archer, G. E., Herndon, J. E., Bigner, D. D., Dranoff, G., & Sampson, J. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3773 · Cited by 617
Self-citationThe multiple pathways to autoimmunity
Theofilopoulos, A. N., Kono, D. H., & Baccala, R. (2017) · Nature Immunology · doi:10.1038/ni.3731 · Cited by 590
Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice
Kujawski, M., Kortylewski, M., Lee, H., Herrmann, A., Kay, H., & Yu, H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35213 · Cited by 581
Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide
Grossman, S. A., Ye, X., Lesser, G., Sloan, A., Carraway, H., Desideri, S., & Piantadosi, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0774 · Cited by 578
Immune microenvironment of gliomas
Gieryng, A., Pszczolkowska, D., Walentynowicz, K. A., Rajan, W. D., & Kaminska, B. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.19 · Cited by 538
Strioga, M., Pasukoniene, V., & Characiejus, D. (2011) · Immunology · doi:10.1111/j.1365-2567.2011.03470.x · Cited by 505
Natural killer cell deficiency
Orange, J. S. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.07.020 · Cited by 504
Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy
Giles, A. J., Hutchinson, M.-K. N. D., Sonnemann, H. M., Jung, J., Fecci, P. E., Ratnam, N. M., Zhang, W., Song, H., Bailey, R., Davis, D., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0371-5 · Cited by 492
Self-citationWainwright, D. A., Balyasnikova, I. V., Chang, A. L., Ahmed, A. U., Moon, K.-S., Auffinger, B., Tobias, A. L., Han, Y., & Lesniak, M. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2130 · Cited by 472
Imtiyaz, H. Z., Williams, E. P., Hickey, M. M., Patel, S. A., Durham, A. C., Yuan, L.-J., Hammond, R., Gimotty, P. A., Keith, B., & Simon, M. C. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39506 · Cited by 461 · cited 1×
“Specifically, HIF2α activation is involved in the M2 polarization axis, with these TAMs being associated with immunosuppression, tumor cell proliferation, angiogenesis, and local invasion, resulting in poor patient outcomes [76, 77].”
BackgroundGlioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype
Gabrusiewicz, K., Rodriguez, B., Wei, J., Hashimoto, Y., Healy, L. M., Maiti, S. N., Thomas, G., Zhou, S., Wang, Q., Elakkad, A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.85841 · Cited by 445
Genard, G., Lucas, S., & Michiels, C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00828 · Cited by 419
Recognition of peptide–MHC class I complexes by activating killer immunoglobulin-like receptors
Stewart, C. A., Laugier-Anfossi, F., Vély, F., Saulquin, X., Riedmuller, J., Tisserant, A., Gauthier, L., Romagné, F., Ferracci, G., Arosa, F. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503594102 · Cited by 406
Kmiecik, J., Poli, A., Brons, N. H. C., Waha, A., Eide, G. E., Enger, P. Ø., Zimmer, J., & Chekenya, M. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.08.013 · Cited by 389
Nishie, A., Ono, M., Shono, T., Fukushi, J., Otsubo, M., Onoue, H., Ito, Y., Inamura, T., 清信, 池., Fukui, M., et al. (1999) · PubMed · Cited by 369
Raychaudhuri, B., Rayman, P., Ireland, J., Ko, J., Rini, B., Borden, E. C., Garcia, J., Vogelbaum, M. A., & Finke, J. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor042 · Cited by 359
The role of the glucocorticoid receptor in inflammation and immunity
Baschant, U., & Tuckermann, J. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.03.058 · Cited by 352
Lawson, J. S., Salmons, B., & Glenn, W. K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00001 · Cited by 340
TGF- downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients
Crane, C. A., Han, S. J., Barry, J. J., Ahn, B. J., Lanier, L. L., & Parsa, A. T. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop009 · Cited by 322
T-cell Dysfunction in Glioblastoma: Applying a New Framework
Woroniecka, K. I., Rhodin, K. E., Chongsathidkiet, P., Keith, K. A., & Fecci, P. E. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0047 · Cited by 315
Self-citationAndaloussi, A. E., & Lesniak, M. S. (2006) · Neuro-Oncology · doi:10.1215/15228517-2006-006 · Cited by 311
Buggert, M., Tauriainen, J., Yamamoto, T., Frederiksen, J., Ivarsson, M. A., Michaëlsson, J., Lund, O., Hejdeman, B., Jansson, M., Sönnerborg, A., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004251 · Cited by 296
Senescence of T Lymphocytes: Implications for Enhancing Human Immunity
Akbar, A. N., Henson, S. M., & Lanna, A. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.09.002 · Cited by 285 · cited 3×
“These mechanisms include: expression of arginase, which decreases the level of L-arginine in the blood/tumor (an amino acid needed for normal T-cell function, specifically translation of the T-cell CD3 zeta chain); secretion of nitric oxide and production of ROS, which themselves are capable of inducing T-cell suppres…”
BackgroundInfluentialMacrophage Infiltration and Heme Oxygenase-1 Expression Correlate with Angiogenesis in Human Gliomas
西江, 昭. (2001) · Medical Entomology and Zoology · doi:10.11501/3181003 · Cited by 278
Schaefer, C., Kim, G. G., Albers, A., Hoermann, K., Myers, E. N., & Whiteside, T. L. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602407 · Cited by 271
Use of dexamethasone in treatment of cerebral edema associated with brain tumors.
Galicich, J. H., French, L. A., & MELBY, J. C. (1961) · PubMed · Cited by 263
CD57+ T lymphocytes and functional immune deficiency
Focosi, D., Bestagno, M., Burrone, O., & Petrini, M. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0809566 · Cited by 252
Otvos, B., Silver, D. J., Mulkearns-Hubert, E. E., Alvarado, A. G., Turaga, S. M., Sorensen, M. D., Rayman, P., Flavahan, W. A., Hale, J. S., Stoltz, K., et al. (2016) · Stem Cells · doi:10.1002/stem.2393 · Cited by 245
Alban, T. J., Alvarado, A. G., Sorensen, M. D., Bayik, D., Volovetz, J., Serbinowski, E., Mulkearns-Hubert, E. E., Sinyuk, M., Hale, J. S., Onzi, G. R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122264 · Cited by 197
Self-citationZagzag, D., Salnikow, K., Chiriboga, L., Yee, H., Lan, L., Ali, M. A., Garcia, R., Demaria, S., & Newcomb, E. W. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700233 · Cited by 189
Fecci, P. E., Sweeney, A. E., Grossi, P. M., Nair, S. K., Learn, C. A., Mitchell, D. A., Cui, X., Cummings, T. J., Bigner, D. D., Gilboa, E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0053 · Cited by 172
Self-citationCytokine Patterns in Brain Tumour Progression
Albulescu, R., Codrici, E., Popescu, I. D., Mihai, S., Necula, L. G., Petrescu, D., Teodoru, M., & Tanase, C. P. (2013) · Mediators of Inflammation · doi:10.1155/2013/979748 · Cited by 171
Dubinski, D., Wölfer, J., Hasselblatt, M., Schneider-Hohendorf, T., Bogdahn, U., Stummer, W., Wiendl, H., & Grauer, O. M. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov280 · Cited by 169
Raychaudhuri, B., Rayman, P. A., Huang, P., Grabowski, M. M., Hambardzumyan, D., Finke, J. H., & Vogelbaum, M. A. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1720-6 · Cited by 148
Self-citationMyeloid-Derived Suppressor Cells
Nagaraj, S., & Gabrilovich, D. I. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-72005-0_22 · Cited by 137
Lin, A., & Yan, W. (2015) · Molecular Medicine · doi:10.2119/molmed.2015.00083 · Cited by 137
Szulzewsky, F., Arora, S., de Witte, L. D., Ulas, T., Markovic, D. S., Schultze, J. L., Holland, E. C., Synowitz, M., Wolf, S. A., & Kettenmann, H. (2016) · Glia · doi:10.1002/glia.23014 · Cited by 124
Steroids in neurooncology: actions, indications, side-effects
Roth, P., Wick, W., & Weller, M. (2010) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32833e5a5d · Cited by 123
Hypoxia-inducible factors: crosstalk between inflammation and metabolism
Shay, J. E. S., & Celeste Simon, M. (2012) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2012.04.004 · Cited by 122
Peereboom, D. M., Alban, T. J., Grabowski, M. M., Alvarado, A. G., Otvos, B., Bayık, D., Roversi, G. A., McGraw, M., Huang, P., Mohammadi, A. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130748 · Cited by 117
Self-citationKriegsman, B. A., Vangala, P., Chen, B. J., Meraner, P., Brass, A. L., Garber, M., & Rock, K. L. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900475 · Cited by 114
Karachi, A., Yang, C., Dastmalchi, F., Sayour, E. J., Huang, J., Azari, H., Long, Y., Flores, C., Mitchell, D. A., & Rahman, M. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz015 · Cited by 113
Suryadevara, C. M., Desai, R. R., Abel, M. L., Riccione, K. A., Batich, K. A., Shen, S. H., Chongsathidkiet, P., Gedeon, P. C., Elsamadicy, A. A., Snyder, D. J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1434464 · Cited by 108
Self-citationCancer Immunoediting in Malignant Glioma
Dunn, G. P., Fecci, P. E., & Curry, W. T. (2012) · Neurosurgery · doi:10.1227/neu.0b013e31824f840d · Cited by 103
Self-citationImmune Checkpoints and Innovative Therapies in Glioblastoma
Romani, M., Pistillo, M. P., Carosio, R., Morabito, A., & Banelli, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00464 · Cited by 97
Mangraviti, A., Raghavan, T., Volpin, F., Skuli, N., Gullotti, D. M., Zhou, J., Asnaghi, L., Sankey, E. W., Liu, A., Wang, Y., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14990-w · Cited by 95
Self-citationAdaptive Tolerance and Clonal Anergy Are Distinct Biochemical States
Chiodetti, L., Choi, S., Barber, D. L., & Schwartz, R. H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.4.2279 · Cited by 91
Wheeler, C. J., Black, K. L., Liu, G., Han, Y., Yu, J. S., Zhang, W., & Lee, P. K. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.9.4927 · Cited by 84
Mieczkowski, J., Kocyk, M., Nauman, P., Gabrusiewicz, K. R., Sielska, M., Przanowski, P., Maleszewska, M., Rajan, W. D., Pszczolkowska, D., Tykocki, T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5310 · Cited by 80
LOX-1+ PMN-MDSC enhances immune suppression which promotes glioblastoma multiforme progression
Chai, E., Zhang, L., & Li, C. (2019) · Cancer Management and Research · doi:10.2147/cmar.s210545 · Cited by 73
Badie, B., Schartner, J. M., Paul, J. S., Bartley, B., Vorpahl, J., & Preston, J. K. (2000) · Journal of neurosurgery · doi:10.3171/jns.2000.93.4.0634 · Cited by 69
Esiri, M. M., & Morris, C. S. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90018-3 · Cited by 56
Iwami, K., Natsume, A., & Wakabayashi, T. (2011) · Neurosurgical Review · doi:10.1007/s10143-011-0320-y · Cited by 56
Moon, W. Y., & Powis, S. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01703 · Cited by 50
Fornara, O., Odeberg, J., Wolmer Solberg, N., Tammik, C., Skarman, P., Peredo, I., Stragliotto, G., Rahbar, A., & Söderberg-Nauclér, C. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1036211 · Cited by 45
Pathophysiological mechanisms regulated by cytokines in gliomas
Christofides, A., Kosmopoulos, M., & Piperi, C. (2014) · Cytokine · doi:10.1016/j.cyto.2014.09.008 · Cited by 45
Reaction of microglial cells in human astrocytomas (preliminary report).
Wierzba‐Bobrowicz, T., Kuchna, I., & Matyja, E. (1994) · PubMed · Cited by 37
MICROGLIA IN GEMISTOCYTIC ASTROCYTOMAS
Geranmayeh, F., Scheithauer, B. W., Spitzer, C., Meyer, F. B., Svensson-Engwall, A.-C., & Graeber, M. B. (2007) · Neurosurgery · doi:10.1227/01.neu.0000249192.30786.67 · Cited by 26
Kakimi, K., Matsushita, H., Hosoi, A., Miyai, M., & Ohara, O. (2014) · OncoImmunology · doi:10.4161/21624011.2014.970464 · Cited by 10
Cited by
Hara, T., Chanoch-Myers, R., Mathewson, N. D., Myskiw, C., Atta, L., Bussema, L., Eichhorn, S. W., Greenwald, A. C., Kinker, G. S., Rodman, C., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.002 · Cited by 593
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
The implications of IDH mutations for cancer development and therapy
Pirozzi, C. J., & Yan, H. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00521-0 · Cited by 382
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Frontiers in the treatment of glioblastoma: Past, present and emerging
Janjua, T. I., Rewatkar, P., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.012 · Cited by 257
Metadata
- Authors
- Grabowski, M. M., Sankey, E. W., Ryan, K. J., Chongsathidkiet, P., Lorrey, S. J., Wilkinson, D. S., & Fecci, P. E.
- Venue
- Journal of Neuro-Oncology
- Published
- 2020-06-15
- Volume
- 151
- Issue
- 1
- Pages
- 3-12
- ISSN
- 0167-594X (ISSN-L)
- 1573-7373
- OpenAlex
- W3035540747
- Cited by
- 270
- References
- 89
- FWCI
- 18.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.